Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I clinical trial of intravenous administration of a conditionally
replicating adenovirus ICOVIR-5 in patients with locally advanced or metastasic malignant

Proposed period of release:
01/09/2010 to 01/12/2011

Name of the Institute(s) or Company(ies)
Institut Català d’Oncologia - IDIBELL, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
ICOVIR-5 (HAd5-DM-E2F-K-Δ24-RGD) is an oncolytic adenovirus derived from HAd5.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HAd5Mastadenoviruswildtype human adenovirus (HAd) - Cwildtype human adenovirus (HAd) serotype 5

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known